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Figure S1
Cumulative incidence of neutrophil engraftment by disease status at transplantation.
HSCT indicates hematopoietic stem cell transplantation; CR, complete remission.
Figure S2
Cumulative incidence of TRM and DAM in whole cohort. HSCT indicates hematopoietic stem cell transplantation; TRM, transplant-related mortality; DAM, disease-associated mortality.
Figure S3
Cumulative incidence of (A) transplant-related mortality and (B) disease-associated mortality by ECOG-PS among non-CR patients. HSCT indicates hematopoietic stem cell transplantation; ECOG, Eastern Cooperative Oncology Group; PS, performance status.
Figure S4
Cumulative incidence of (A) transplant-related mortality and (B) disease-associated mortality according to sIL-2R level among non-CR patients. HSCT indicates hematopoietic stem cell transplantation; CR, complete remission.
Figure S5
(A) Overall survival rate and MST for all patients with ECOG-PS 0-2.
(B) Overall survival rate and MST by disease status at transplantation (CR vs. non-CR) for patients with ECOG-PS 0-2.
Cumulative incidence of (C) transplant-related mortality and (D) disease-associated mortality by disease status at transplantation for patients with ECOG-PS 0-2.
Unadjusted 3-year probability of overall survival was 27.9% (95% CI, 16.2%-40.8%) and
MST was 10.7 months for all patients with ECOG-PS 0-2. Among these patients, Pt-CR had a higher 3-year probability of survival than Pt-non-CR (45.9% [95% CI, 21.4%-67.5%] vs. year overall survival; CI, confidence interval. disease-associated mortality by disease status at transplantation. Three-year overall survival rates were 43.6% (95% CI, 20.3%-64.9%), 23.1% (95% CI, 8.3%-42.1%) and 6.7% (95% CI, 0.4%-26.0%) for patients in CR, PR/SD, and PD, respectively. Survival rates were significantly lower for patients with PR/SD than for those in CR (P = 0.041), and survival rates were significantly lower for patients with PD than for those with PR/SD (P = 0.022) and those in CR (P < 0.001). Cumulative incidence of TRM was significantly higher in patients with PD (73.3%; 95% CI, 38.6%-90.4%) than in those with PR/SD (38.5%; 95% CI, 19.9%-56.8%; P = 0.035) and those in CR (28.2%; 95% CI, 9.5%-50.6%; P = 0.001). TRM in patients with PR/SD tended to be higher than that in patients in CR, albeit without statistical significance (P = 0.198). Cumulative incidence of DAM was not significant different among patients in CR (28.2%; 95% CI; 9.5%-50.6%), those with PR/SD (38.5%; 95% CI, 18.0%-58.7%), and those with PD (20.0%; 95% CI, 4.4%-43.7%). CR indicates complete remission; PR, partial response; SD, stable disease; PD, progressive disease; CI, confidence interval;
Figure S6
TRM, transplant-related mortality; DAM, disease-associated mortality.
